Skip to content

Study · Observational study · 2014

2 results

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.

Chang L, Lembo AJ, Lavins BJ, Shiff SJ, Hao X, Chickering JG, Jia XD, Currie MG, Kurtz CB, Johnston JM

Alimentary pharmacology & therapeutics13 Oct 2014Cited by 26 (Europe PMC)

PMID25312449 (opens in a new tab)PMCIDPMC4278547 (opens in a new tab)DOI10.1111/apt.12985 (opens in a new tab)PepBankPUB-25312449
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In CIC patients with more-severe abdominal pain, linaclotide significantly improved all symptoms and global measures.

    In plain wordsIn CIC patients with more-severe abdominal pain, linaclotide improved symptoms and global measures.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedSymptoms and global measures in more-severe pain subgroup
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    145 μg or 290 μg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Linaclotide significantly improved all symptoms and global measures in both subpopulations.
    3 context sentences
    Summary · context
    In two phase 3 trials, patients meeting modified Rome II CIC criteria were assigned to linaclotide 145 μg, 290 μg, or placebo once daily.
    Summary · context
    Patients rated abdominal and bowel symptoms daily during 2-week pre-treatment and 12-week treatment periods.
    Summary · context
    Linaclotide's effect on symptoms and global measures [constipation severity, health-related quality of life (HRQOL), treatment satisfaction] and their inter-relationships were assessed in post hoc analyses of abdominal pain subpopulations.
  2. 02HumanObservational studyEfficacy outcome

    In CIC patients with less-severe abdominal pain, linaclotide significantly improved all symptoms and global measures.

    In plain wordsIn CIC patients with less-severe abdominal pain, linaclotide improved symptoms and global measures.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedSymptoms and global measures in less-severe pain subgroup
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    145 μg or 290 μg once daily · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Linaclotide significantly improved all symptoms and global measures in both subpopulations.
    3 context sentences
    Summary · context
    In two phase 3 trials, patients meeting modified Rome II CIC criteria were assigned to linaclotide 145 μg, 290 μg, or placebo once daily.
    Summary · context
    Patients rated abdominal and bowel symptoms daily during 2-week pre-treatment and 12-week treatment periods.
    Summary · context
    Linaclotide's effect on symptoms and global measures [constipation severity, health-related quality of life (HRQOL), treatment satisfaction] and their inter-relationships were assessed in post hoc analyses of abdominal pain subpopulations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00765882

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Forest Laboratoriesn = 633Sept 2008 to Aug 2009

Chronic Constipation

Trial pageClinicalTrials.govUpdated 30 Jan 2013
CompletedPhase 3Results postedNCT00730015

Trial of Linaclotide in Patients With Chronic Constipation

Ironwood Pharmaceuticals, Inc.n = 643Aug 2008 to Oct 2009

Chronic Constipation

Trial pageClinicalTrials.govUpdated 30 Jan 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.